1
|
Le Levreur B, Frantz S, Lambert M, Chansel-Debordeaux L, Bernard V, Carriere J, Verdy G, Hocke C. [No improvement in live birth rate after luteal phase support by GnRH agonist]. Gynecol Obstet Fertil Senol 2023; 51:249-255. [PMID: 36871830 DOI: 10.1016/j.gofs.2023.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 01/20/2023] [Accepted: 02/18/2023] [Indexed: 03/06/2023]
Abstract
OBJECTIVES To evaluate the impact of adding a GnRH agonist (GnRH-a) in luteal phase support (LPS) on live birth rates in IVF/ICSI in antagonist protocols. METHODS In total, 341 IVF/ICSI attempts are analyzed in this retrospective study. Patients were divided into two groups: A f: LPS with progesterone alone (179 attempts) between March 2019 and May 2020; B: LPS with progesterone and an injection of triptorelin (GnRH-a) 0.1mg 6 days after oocyte retrieval (162 attempts) between June 2020 and June 2021. The primary outcome was live birth rate. The secondary outcomes were miscarriage rate, pregnancy rate and ovarian hyperstimulation syndrome rate. RESULTS The baseline characteristic are identical between the two groups except the infertility duration (longer in the group B). There was no significant difference between the two groups in live birth rate (24.1% versus 21.2%), pregnancy rate (33.3% versus 28.1%), miscarriage rate (4.9% versus 3.4%) and no increase the SHSO rate. The multivariate regression analysis after adjustment for age, ovarian reserve and infertility duration did not reveal a significant difference in live birth rate between the two groups. CONCLUSION In this study, the results showed no statistically significant association with the single injection of a GnRH-a in addition to progesterone on live birth rate in luteal phase support.
Collapse
Affiliation(s)
- B Le Levreur
- Service de gynécologie et de médecine de la reproduction, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
| | - S Frantz
- Service de gynécologie et de médecine de la reproduction, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - M Lambert
- Service de gynécologie et de médecine de la reproduction, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - L Chansel-Debordeaux
- Service de biologie de la reproduction-CECOS, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - V Bernard
- Service de gynécologie et de médecine de la reproduction, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - J Carriere
- Service de gynécologie et de médecine de la reproduction, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - G Verdy
- Pôle santé publique, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - C Hocke
- Service de gynécologie et de médecine de la reproduction, CHU de Bordeaux, centre Aliénor d'Aquitaine, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| |
Collapse
|
2
|
Bernard V, Elhammali A, Lin D, Pant S, Tzeng C, Bhutani M, Maitra A, Navin N, Taniguchi C. Single Cell Sequencing of Pancreatic Ductal Adenocarcinoma Reveals a Paradoxical Immunosuppressive Microenvironment Following Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Rohan T, Andrasina T, Juza T, Matkulcik P, Červinka D, Svobodova I, Novotná V, Bernard V, Valek V, Goldberg SN. Experimental model of occluded biliary metal stent recanalization using irreversible electroporation via a tubular catheter. Int J Hyperthermia 2021; 38:393-401. [PMID: 33682581 DOI: 10.1080/02656736.2021.1875061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
PURPOSE To demonstrate the feasibility of irreversible electroporation (IRE) for treating biliary metal stent occlusion in an experimental liver model. METHODS AND MATERIALS IRE was performed using an expandable tubular IRE-catheter placed in nitinol stents in the porcine liver. A 3-electrode IRE-catheter was connected to an IRE-generator and one hundred 100μs pulses of constant voltage (300, 650, 1000, and 1300 V) were applied. Stent occlusion was simulated by insertion of liver tissue both ex vivo (n = 94) and in vivo in 3 pigs (n = 14). Three scenarios of the relationship between the stent, electrodes, and inserted tissue (double contact, single contact, and stent mesh contact) were studied. Electric current was measured and resistance and power calculated. Pigs were sacrificed 72 h post-procedure. Harvested samples (14 experimental, 13 controls) underwent histopathological analysis. RESULTS IRE application was feasible at 300 and 650 V for the single and double contact setup in both ex vivo and in vivo studies. Significant differences in calculated resistance between double contact and single contact settings were observed (ex-vivo p ˂ 0.0001, in-vivo p = 0.02; Mann-Whitney). A mild temperature increase of the surrounding liver parenchyma was noted with increasing voltage (0.9-5.9 °C for 300-1000 V). The extent of necrotic changes in experimental samples in vivo correlated with the measured electric current (r2 = 0.39, p = 0.01). No complications were observed during or after the in-vivo procedure. CONCLUSION Endoluminal IRE using an expandable tubular catheter in simulated metal stent occlusion is feasible. The relationship of active catheter electrodes to stent ingrowth tissue can be estimated based on resistance values.
Collapse
Affiliation(s)
- T Rohan
- Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic
| | - T Andrasina
- Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic
| | - T Juza
- Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic
| | - P Matkulcik
- Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic
| | - D Červinka
- Faculty of Electrical Engineering and Communication, Department of Power Electrical and Electronic Engineering, Brno University of Technology, Brno, Czech Republic
| | - I Svobodova
- Department of Pathology, St. Anne's University Hospital Brno, Brno, Czech Republic
| | - V Novotná
- Faculty of Electrical Engineering and Communication, Department of Power Electrical and Electronic Engineering, Brno University of Technology, Brno, Czech Republic
| | - V Bernard
- Faculty of Medicine, Department of Biophysics, Masaryk University, Brno, Czech Republic
| | - V Valek
- Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic
| | | |
Collapse
|
4
|
Hocké C, Diaz M, Bernard V, Frantz S, Lambert M, Mathieu C, Grellety-Cherbero M. [Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol 2021; 49:394-413. [PMID: 33757926 DOI: 10.1016/j.gofs.2021.03.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Genitourinary menopause syndrome (SGUM) is defined as a set of symptoms associated with a decrease of estrogen and other sexual steroids during menopause. The main symptoms are vulvovaginal (dryness, burning, itching), sexual (dyspareunia), and urinary (urinary infections, pollakiuria, nycturia, pain, urinary incontinence by urgenturia). SGUM leads to an alteration of the quality of life, and affects especially women's sexuality. OBJECTIVE The objective of this review was to elaborate guidelines for clinical practice regarding the management of SGUM in postmenopausal women, and in particular, in women with a history of breast cancer, treated or not with hormone therapy. MATERIALS AND METHODS A systematic review of the literature on SGUM management was conducted on Pubmed, Medline and Cochrane Library. Recommendations from international scholarly societies were also taken into account: International Menopause Society (IMS) https://www.imsociety.org, The North American Menopause Society (NAMS) https://www.menopause.org, Canadian Menopause Society https://www.sigmamenopause.com, European Menopause and Andropause Society (EMAS) https://www.emas-online.org, International Society for the Study of Women's Sexual Health (ISSWSH) https://www.isswsh.org. RESULTS Vaginal use of lubricants, moisturizers and hyaluronic acid improves the symptoms of SGUM and may be offered to all patients. For postmenopausal women, local estrogen will be preferred to the oral route because of their safety and efficacy on all symptoms of SGUM during low-dose use. Prasterone is a local treatment that can be proposed as an effective alternative for the management of dyspareunia and sexual function disorder. Current data on oral testosterone, tibolone, oral or transdermal DHEA and herbal medicine are currently limited. Ospemifène, which has shown a significant improvement in sexual symptoms, is not currently marketed in France. In the particular case of women with a history of breast cancer, non-hormonal regimens are a first-line therapy. Current data on the risk of breast cancer recurrence when administering low-dose local estrogen are reassuring but do not support a conclusion that this treatment is safe. CONCLUSION SGUM is a common symptom that can affect the quality of life of postmenopausal women. A treatment should be systematically proposed. Local non-hormonal treatment may be offered in all women. Local low-dose estrogen therapy and Prasterone has shown an interest in the management of symptoms. In women before a history of breast cancer, local non-hormonal treatment should be offered first-line. The safety of low-dose local estrogen therapy and Prasterone cannot be established at this time. Other alternatives exist but are not currently recommended in France due to lack of data.
Collapse
Affiliation(s)
- C Hocké
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
| | - M Diaz
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - V Bernard
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - S Frantz
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - M Lambert
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - C Mathieu
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - M Grellety-Cherbero
- Service de chirurgie gynécologique et médecine de la reproduction, centre Aliénor d'Aquitaine, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| |
Collapse
|
5
|
Fraticelli L, Claustre C, Boniol L, Chambost M, Maiello E, Bernard V, Dodane-Loyenet A, Martinez M, El Khoury C. Comparaison des durées d’incapacité totale de travail attribuées par médecins légistes et urgentistes. Ann Fr Med Urgence 2020. [DOI: 10.3166/afmu-2020-0249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Objectif : Comparer les durées d’incapacité totale de travail (ITT) attribuées à la suite d’un passage aux urgences par le médecin urgentiste en charge du patient, et celles attribuées a posteriori par des médecins urgentistes et des médecins légistes.
Matériel et méthodes : À partir de l’Observatoire régional des accidents et des traumatismes (ORAT), les accidents de la route et de la vie courante ayant conduit à l’attribution d’une ITT ont été inclus. Trois légistes et trois urgentistes ont attribué a posteriori des durées d’ITT en nombre de jours à partir des informations recueillies dans l’ORAT. La qualité intra- et interprescripteurs a été mesurée. La concordance a été mesurée avec le coefficient de corrélation intraclasse (CCI) et son intervalle de confiance à 95 %. Un accord était observé entre prescripteurs si l’écart entre leurs ITT était inférieur ou égal à 20 % de la moyenne des ITT attribuées.
Résultats : La concordance entre légistes était jugée modérée (CCI : 0,67 [0,51 ; 0,80]), de même entre urgentistes (CCI : 0,62 [0,50 ; 0,72]) et entre légistes et urgentistes (CCI : 0,66 [0,59 ; 0,71]). Cependant, seulement 16 % des situations sont en accord. Parmi ces dernières, les patients ne présentaient pas de caractéristiques communes. Ils consultaient généralement le jour même de l’accident et présentaient le plus souvent des lésions à la tête, à la face ou au cou. Parmi les situations de désaccord, les patients présentaient plus fréquemment des lésions à la colonne vertébrale et étaient associés à un handicap n’affectant pas la fonction normale (IIS 1).
Conclusion : Nous avons observé une grande hétérogénéité dans l’évaluation entre légistes et urgentistes, qui peut induire une iniquité dans le traitement judiciaire des blessures et dans le suivi médical des victimes.
Collapse
|
6
|
Bernard V, El Khoury C, Fraticelli L. P3614Impact of renal dysfunction in patients with acute myocardial infarction on early management and outcome: a first observational French study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Kidney dysfunction (KD) is largely associated to cardiovascular mortality.
Purpose
Analyse early management and outcome in real life of ST segment elevation myocardial infarction (STEMI) patients with KD compared to STEMI patients with normal renal function.
Methods
Using 10 years' data from OSCAR regional registry, we investigated the early management and outcome of all patients with STEMI. Kidney dysfunction (KD) has been defined by creatinine clearance (CrCl) <90mL/min and was assessed using Cockcroft-Gault (CG) equation. Among them, two groups were identified: patients with normal kidney function (NKF) (CrCl ≥90mL/min) and patients with KD (CrCl <90mL/min). KD patients were stratified into 3 groups: patients with mild KD (CrCl 60–90mL/min), patients with moderate KD (CrCl 30–60mL/min) and patients with severe KD (CrCl <30mL/min). The comparison of the groups concerned patient characteristics, therapeutic strategy and follow-up at 1, 6 and 12 months.
Results
Our study included 8 003 STEMI patients from 2009 to 2018, 4 234 (52.9%) of them with KD. Among these, 2441 (57.6%) patients had mild KD, 1494 (35.3%) moderate KD and 299 (7.1%) severe KD. NKF patients were younger than KD group (54 [48–61] vs 72 [63–81]). KD patients had more cardiovascular risk factors such as diabetes, hypertension and personal history of coronary disease (p<0.001), but were less smokers (p<0,001). KD patients presented less often chest pain, and more dyspnea or cardiac arrest (p<0,001). There was no difference in symptom-first medical contact delay (p=0.30). More than 14% of patients with KD presented with Killip≥2. In the KD group location of infarction was more often anterior and lateral. In-hospital treatment differed among the groups: KD patients received less prasugrel (11% vs 20%), ticagrelor (44% vs 49%), enoxaparin (70% vs 80%), morphine (29% vs 39%) or other analgesic (30% vs 35%), but more clopidogrel (33% vs 23%), diuretics (3% vs 0,7%) and catecholamines (5% vs 2%) (p<0.001). In-hospital mortality was higher in the KD group (9% vs 1%, p<0.001). One-year mortality was 14% in the KD group compared to 2% for patients with NKF (p<0.001). Also, in-hospital mortality was increasing exponentially with KD severity (2%, 8% and 24% for mild, moderate and severe KD) (p<0,001) as well as 1-year mortality (respectively 1%, 6% and 12% after 1 year) (p<0,001).
Conclusion
Kidney insufficiency is an independent risk factor for death in patients after myocardial infarction and was associated with poor prognosis at short- and long-term. We observed that mortality increased with KD severity. Despite a high cardiovascular risk, KD patients presenting STEMI are less likely to receive therapy, while having more co-morbidities and extended infarction. To achieve an optimal medical care of KD patients with STEMI, we should introduce evidence-based therapies in the acute phase.
Collapse
Affiliation(s)
- V Bernard
- University Hospital Gabriel Montpied, Emergency, Clermont-Ferrand, France
| | - C El Khoury
- Hospital Center Lucien Hussel, Emergency, Vienne, France
| | - L Fraticelli
- Hospital Center Lucien Hussel, Emergency, Vienne, France
| |
Collapse
|
7
|
Warling O, Oger AF, Lamproye A, Bernard V, Marting A, Detry O, Louis E, Delwaide J. [Alcoholic hepatitis]. Rev Med Liege 2019; 74:326-331. [PMID: 31206275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Alcoholic hepatitis is a syndrome defined primarily by the clinical onset of jaundice in patients with a concomitant heavy consumption of alcoholic beverages. This pathology is managed by alcohol withdrawal with a 30-day survival rate of 90 %. For patients with severe alcoholic hepatitis, with a Maddrey score greater than 32 (taking into account bilirubin and prothrombin time), treatment with corticosteroids is discussed provided that a possible infection can be sufficiently excluded or adequately managed. The administration of corticosteroids is continued for 28 days if the Lille score, calculated after 7 days of treatment, is favourable (inferior to 0.45), leading to a survival rate of 80-90 %. However, if the Lille score is unfavourable (superior to 0.45), the prognosis is bad, with a survival of only 25-30 % at 6 months. Special attention needs to be paid to assure a sufficient caloric intake during the treatment period for a successful management. Liver transplantation, previously prohibited for this indication, can be discussed under certain circumstances. However, the success of treatment is contingent upon the alcohol withdrawal. Innovative drugs are currently under investigation to improve the prognosis of this condition.
Collapse
Affiliation(s)
- O Warling
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| | - A F Oger
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| | - A Lamproye
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| | - V Bernard
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| | - A Marting
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| | - O Detry
- Service de Chirurgie abdominale, CHU Liège, Belgique
| | - E Louis
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| | - J Delwaide
- Service de Gastroentérologie-Hépatologie, CHU Liège, Belgique
| |
Collapse
|
8
|
Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol 2019; 29:223-229. [PMID: 29045505 DOI: 10.1093/annonc/mdx542] [Citation(s) in RCA: 150] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background Detection of circulating tumor DNA can be limited due to their relative scarcity in circulation, particularly while patients are actively undergoing therapy. Exosomes provide a vehicle through which cancer-specific material can be enriched from the compendium of circulating non-neoplastic tissue-derived nucleic acids. We carried out a comprehensive profiling of the pancreatic ductal adenocarcinoma (PDAC) exosomal 'surfaceome' in order to identify surface proteins that will render liquid biopsies amenable to cancer-derived exosome enrichment for downstream molecular profiling. Patients and methods Surface exosomal proteins were profiled in 13 human PDAC and 2 non-neoplastic cell lines by liquid chromatography-mass spectrometry. A total of 173 prospectively collected blood samples from 103 PDAC patients underwent exosome isolation. Droplet digital PCR was used on 74 patients (136 total exosome samples) to determine baseline KRAS mutation call rates while patients were on therapy. PDAC-specific exosome capture was then carried out on additional 29 patients (37 samples) using an antibody cocktail directed against selected proteins, followed by droplet digital PCR analysis. Exosomal DNA in a PDAC patient resistant to therapy were profiled using a molecular barcoded, targeted sequencing panel to determine the utility of enriched nucleic acid material for comprehensive molecular analysis. Results Proteomic analysis of the exosome 'surfaceome' revealed multiple PDAC-specific biomarker candidates: CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE, and HIST2H2BF. KRAS mutations in total exosomes were detected in 44.1% of patients undergoing active therapy compared with 73.0% following exosome capture using the selected biomarkers. Enrichment of exosomal cargo was amenable to molecular profiling, elucidating a putative mechanism of resistance to PARP inhibitor therapy in a patient harboring a BRCA2 mutation. Conclusion Exosomes provide unique opportunities in the context of liquid biopsies for enrichment of tumor-specific material in circulation. We present a comprehensive surfaceome characterization of PDAC exosomes which allows for capture and molecular profiling of tumor-derived DNA.
Collapse
Affiliation(s)
- J Castillo
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - V Bernard
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.,The University of Texas MD Anderson Cancer UTHealth Graduate School of Biomedical Sciences, Houston, USA
| | - F A San Lucas
- Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - K Allenson
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M Capello
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - D U Kim
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | | | - F C Mulu
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - B M Stephens
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - J Huang
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - H Wang
- McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - A A Momin
- McCombs Institute for the Early Detection and Treatment of Cancer, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R O Jacamo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M Katz
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R Wolff
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M Javle
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - G Varadhachary
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - I I Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S Hanash
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - A Maitra
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.,Department of Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - H Alvarez
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.,Department of Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, USA
| |
Collapse
|
9
|
Beldjoudi G, Bernard V, Tanguy R. EP-1739 Indicators evaluation for robust dose prescription in SBRT of peripheral non-small cell lung cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32159-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Pokorná J, Staffa E, Čan V, Bernard V, Mornstein V, Farkašová M, Zetelolová A, Kala Z. Intestinal resection of a porcine model under thermographic monitoring. Physiol Meas 2019; 40:014003. [DOI: 10.1088/1361-6579/aafa8e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
11
|
Schweich M, De VA, Sacré F, Bernard V, Michels V. [Scorbut, historic disease ?]. Rev Med Liege 2018; 73:541-543. [PMID: 30431241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Scurvy, a disease caused by a deficit in vitamin C, is again described in Europe nowadays. This condition is associated with poverty and malnutrition, as found in developing countries. However, denutrition may also occur with a "western" lifestyle that can lead to nutriment deficiencies. In the following report is described a case of scurvy in a person suffering from alcoholism.
Collapse
Affiliation(s)
- M Schweich
- Gastro-entérologie, CHBA, Liège, Belgique
| | | | - F Sacré
- Gastro-entérologie, CHBA, Liège, Belgique
| | - V Bernard
- Gastro-entérologie, CHBA, Liège, Belgique
| | - V Michels
- Gastro-entérologie, CHBA, Liège, Belgique
| |
Collapse
|
12
|
Yossi S, Lamberth F, Marchand V, Cervellera M, Mammar V, Khodri M, Nguyen D, Fafi S, Bernard V, Portier N, Coquard R, Barbet N. Radiothérapie par modulation d’intensité des cancers du sein sur Halcyon : résultats préliminaires. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer 2018; 91:47-55. [PMID: 29331751 DOI: 10.1016/j.ejca.2017.12.016] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/25/2017] [Accepted: 12/09/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND We aimed at identifying deleterious genomic alterations from untreated head and neck squamous cell carcinoma (HNSCC) patients, and assessing their prognostic value. PATIENTS AND METHODS We retrieved 122 HNSCC patients who underwent primary surgery. Targeted NGS was used to analyse a panel of 100 genes selected among the most frequently altered genes in HNSCC and potential therapeutic targets. We selected only deleterious (activating or inactivating) single nucleotide variations, and copy number variations for analysis. Univariate and multivariate analyses were performed to assess the prognostic value of altered genes. RESULTS A median of 2 (range: 0-10) genomic alterations per sample was observed. Most frequently altered genes involved the cell cycle pathway (TP53 [60%], CCND1 [30%], CDKN2A [25%]), the PI3K/AKT/MTOR pathway (PIK3CA [12%]), tyrosine kinase receptors (EGFR [9%], FGFR1 [5%]) and cell differentiation (FAT1 [7%], NOTCH1 [4%]). TP53 mutations (p = 0.003), CCND1 amplifications (p = 0.04), CDKN2A alterations (p = 0.02) and FGFR1 amplifications (p = 0.003), correlated with shorter overall survival (OS). The number of genomic alterations was significantly higher in the HPV-negative population (p = 0.029) and correlated with a shorter OS (p < 0.0001). Only TP53 mutation and FGFR1 amplification status remained statistically significant in the multivariate analysis. CONCLUSION These results suggest that genomic alterations involving the cell cycle (TP53, CCND1, CDKN2A), as well as FGFR1 amplifications and tumour genomic alterations burden are prognostic biomarkers and might be therapeutic targets for patients with HNSCC.
Collapse
Affiliation(s)
- C Dubot
- Department of Medical Oncology, Institut Curie, Paris, Saint-Cloud, France; Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France.
| | - V Bernard
- Unit of Bioinformatics, Next Generation Sequencing Platform-ICGex, Institut Curie, Paris, France
| | - M P Sablin
- Department of Medical Oncology, Institut Curie, Paris, Saint-Cloud, France
| | - S Vacher
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - W Chemlali
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - A Schnitzler
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
| | - G Pierron
- Unit of Somatic Genomics, Department of Genetics, Institut Curie, Paris, France
| | - K Ait Rais
- Unit of Somatic Genomics, Department of Genetics, Institut Curie, Paris, France
| | - N Bessoltane
- Unit of Bioinformatics, Next Generation Sequencing Platform-ICGex, Institut Curie, Paris, France
| | - E Jeannot
- Department of Biopathology, Institut Curie, Paris, France
| | - J Klijanienko
- Department of Biopathology, Institut Curie, Paris, France
| | - O Mariani
- Department of Biopathology, Institut Curie, Paris, France
| | - T Jouffroy
- Department of Surgery, Institut Curie, Paris, France
| | - V Calugaru
- Department of Radiotherapy, Institut Curie, Paris, France
| | - C Hoffmann
- Department of Surgery, Institut Curie, Paris, France
| | - M Lesnik
- Department of Surgery, Institut Curie, Paris, France
| | - N Badois
- Department of Surgery, Institut Curie, Paris, France
| | - F Berger
- Department of Biostatistics, Institut Curie, Paris, France
| | - C Le Tourneau
- Department of Medical Oncology, Institut Curie, Paris, Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France
| | - M Kamal
- Department of Medical Oncology, Institut Curie, Paris, Saint-Cloud, France
| | - I Bieche
- Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France; EA7331, Paris Descartes University, Faculty of Pharmaceutical and Biological Sciences, Paris, France
| |
Collapse
|
14
|
Cabel L, Bieche I, Aparicio T, Svrcek M, Zaanan A, Afchain P, Di Fiore F, Gornet JM, Le Corre D, Vacher S, Callens C, Bernard V, Laurent-Puig P, Bidard FC. Frequent ERBB3 (HER3) activating mutations in small bowel adenocarcinomas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga J, Proudhon C, Bidard FC. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol 2017; 28:1996-2001. [DOI: 10.1093/annonc/mdx212] [Citation(s) in RCA: 172] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
16
|
Bernard V, Fraticelli L, Guy A, Eydoux N, Serre P, El Khoury C. P5568Outcome of patients with acute myocardial infarction complicated by pre-hospital cardiac arrest. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- V. Bernard
- Civils Hospices of Lyon, Emergency Department, Lyon, France
| | - L. Fraticelli
- Hospital Center Lucien Hussel, RESCUe Network, Vienne, France
| | - A. Guy
- Civils Hospices of Lyon, Emergency Department, Lyon, France
| | - N. Eydoux
- Hospital Center Lucien Hussel, RESCUe Network, Vienne, France
| | - P. Serre
- Hospital Center Lucien Hussel, Emergency Department, Vienne, France
| | - C. El Khoury
- Hospital Center Lucien Hussel, Emergency Department, Vienne, France
| | | |
Collapse
|
17
|
Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol 2017; 28:741-747. [PMID: 28104621 PMCID: PMC5834026 DOI: 10.1093/annonc/mdx004] [Citation(s) in RCA: 324] [Impact Index Per Article: 46.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2016] [Indexed: 02/03/2023] Open
Abstract
Background Exosomes arise from viable cancer cells and may reflect a different biology than circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived DNA (exoDNA) to cfDNA in liquid biopsies of patients with pancreatic ductal adenocarcinoma (PDAC). Patients and methods Patient samples were obtained between 2003 and 2010, with clinically annotated follow up to 2015. Droplet digital PCR was performed on exoDNA and cfDNA for sensitive detection of KRAS mutants at codons 12/13. A cumulative series of 263 individuals were studied, including a discovery cohort of 142 individuals: 68 PDAC patients of all stages; 20 PDAC patients initially staged with localized disease, with blood drawn after resection for curative intent; and 54 age-matched healthy controls. A validation cohort of 121 individuals (39 cancer patients and 82 healthy controls) was studied to validate KRAS detection rates in early-stage PDAC patients. Primary outcome was circulating KRAS status as detected by droplet digital PCR. Secondary outcomes were disease-free and overall survival. Results KRAS mutations in exoDNA, were identified in 7.4%, 66.7%, 80%, and 85% of age-matched controls, localized, locally advanced, and metastatic PDAC patients, respectively. Comparatively, mutant KRAS cfDNA was detected in 14.8%, 45.5%, 30.8%, and 57.9% of these individuals. Higher exoKRAS MAFs were associated with decreased disease-free survival in patients with localized disease. In the validation cohort, mutant KRAS exoDNA was detected in 43.6% of early-stage PDAC patients and 20% of healthy controls. Conclusions Exosomes are a distinct source of tumor DNA that may be complementary to other liquid biopsy DNA sources. A higher percentage of patients with localized PDAC exhibited detectable KRAS mutations in exoDNA than previously reported for cfDNA. A substantial minority of healthy samples demonstrated mutant KRAS in circulation, dictating careful consideration and application of liquid biopsy findings, which may limit its utility as a broad cancer-screening method.
Collapse
Affiliation(s)
| | | | - F. A. San Lucas
- Translational Molecular Pathology
- Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - G. Scelo
- Genetic Epidemiology Group International Agency for Research on Cancer, Lyon, France
| | | | | | | | | | - M. Katz
- Departments of Surgical Oncology
| | - M. J. Overman
- Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - L. Foretova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - E. Fabianova
- Regional Authority of Public Health in Banska Bystrica, Banska Bystrica, Slovakia
| | - I. Holcatova
- Institute of Public Health and Preventive Medicine, 2nd Faculty of Medicine, Charles University, Prague
| | - V. Janout
- Department of Preventive Medicine, Palacky University of Medicine, Olomouc
- Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - F. Meric-Bernstam
- Department of Investigational Cancer Therapeutics and the Institute for Personalized Cancer Therapy, Houston
| | | | | | - G. Varadhachary
- Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - P. Brennan
- Genetic Epidemiology Group International Agency for Research on Cancer, Lyon, France
| | - S. Hanash
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - D. Li
- Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - A. Maitra
- Pathology
- Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - H. Alvarez
- Pathology
- Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, USA
| |
Collapse
|
18
|
Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard FC, Servois V, Comte A, Belin L, Sigal B, Bièche I. Abstract PD1-06: Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Genomic profile of breast cancer metastases (M) may differ from that of the primary tumor (PT). In a multicenter prospective study (ESOPE, NCT 01956552) including 130 patients with biopsies of the first metastatic deposit, we have shown that luminal breast cancers are the most prone to phenotypical subtype changes (Comte et al, ASCO 2016#550). We report here the first results of a comparative PT/M targeted next generation sequencing (NGS) mutational analysis.
Methods
Of 130 patients, 117 paired PT/M samples obtained before any treatment were available for analysis. Targeted Sequencing was done using Illumina Hiseq2500 technology with a custom made 95 breast cancer associated genes panel. Sequence data were aligned to the human reference genome (hg19) using Bowtie2 algorithm. Median depth was 607X and 87% of targets achieved 100X depth. SNVs and indels were called using GATK UnifiedGenotyper. We retained COSMIC confirmed non synonymous, exonic/splice variants and observed at a frequency lower than 0,1% in population. Further confirmation of detected variants was performed with comparison to public databases (cbioportal, tumorportal), and potential pathogenicity was evaluated with 4 different public algorithms. We present here the results obtained from the first 35 matched PT/M samples (liver mets 68%), focusing analysis on 40 genes including PIK3CA (20 genes), ER (6 genes) and MAPK (11 genes) pathways, RUNX1, CDH1 and TP53 genes.
Results
Patients characteristics are representative of patients with first line metastatic breast cancer (Comte et al, ASCO 2016#550). Among the 40 genes analyzed in the 70 samples, we detected 134 somatic mutations (70 in PT and 64 in M) including 15 indels and 119 SNV. Among these 134 mutations there were 74 different mutations (66SNV and 8 indels) classified pathogenic for 26 and of unknown pathogenicity for 48 of them. We detected at least 1 mutation in 31 PT and in 28 M. Median numbers of mutations were 1 in PT (range 1-9) and 1 in M (range1-22) samples (p=0.295, Wilcoxon rank sum test). Top ten mutated genes in PT included PIK3CA, TP53, NCOR1, NF1, GATA3, CDH1, ERBB3, PTEN, HRAS, INPP4B. In M samples, the 10 top genes were PIK3CA, TP53, ERBB3, AKT3, CDH1, ERBB4, GATA3, INPP4B, MET, MTOR. Only 3 ESR1 mutations were detected, including 1 PT/M pair and 1 M. Beyond highly shared PIK3CA and TP53 mutations, overall crude PT/M discordance rate was 31%. Analysis by histological subtypes showed PT and M specific mutational profiles, suggesting a role in ERB gene family (notably ERBB3) and MAPK driven pathways in early metastatic progression. Specific metastatic site analysis suggested enrichment in MAPK pathway mutations in liver metastases when compared to other sites. Variant allelic fractions were globally not significantly different between PT and M samples.
Conclusion
In this prospective multicenter series of systematic biopsies of first metastases, we report a targeted mutational analysis of matched PT and M samples not modified by previous therapy exposure. Early analyses suggest specific genotypical changes according to tumor subtype and/or metastatic site. Extended and updated results will be reported at the meeting.
Citation Format: Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard F-C, Servois V, Comte A, Belin L, Sigal B, Bièche I. Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-06.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Boulai
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Baulande
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - P Legoix-Ne
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Bernard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Benhamo
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - EGC Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - W Chemlali
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Campone
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - TD Bachelot
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Giacchetti
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - J Bonneterre
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - B Sigal
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
19
|
Callens C, Bessoltane N, Ngo C, Chemlali W, Becette V, Bernard V, Delattre O, Lemonnier J, Mouret-Reynier MA, Andre F, Bieche I, Lerebours F. Abstract P3-04-09: Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-04-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CARMINA02 is a non-comparative multicenter phase II randomized trial evaluating the clinical response rate after up to 6 months of neoadjuvant endocrine therapy (NET) in HR+/HER2- patients with 1 mg anastrozole (Arm A) or 500 mg fulvestrant (Arm B). Secondary objectives included predictive markers of response and outcome. Between 2007 and 2011, 116 women with operable infiltrating breast adenocarcinoma T2-T4 N0-N3 M0 were randomized. Clinical response rates at 6 months (RECIST criteria) were 52.6% [95%CI 41-64%] in Arm A and 36.8% [95%CI 25-49%] in Arm B (Cancer 2016, in press). We aimed to identify the molecular predictive markers of resistance or sensitivity common to both treatments.
Methods: Ninety tumor RNA from clinical responder (n=34) and resistant patients (n=23) treated in arms A or B have been sequenced with Illumina Hiseq2500 technology leading to 2x100-nt paired-end RNA-seq reads. These samples are from pre-treatment (29 in arm A, 28 in arm B) and post-treatment tumors (6 months after, 17 in arm A and 16 in arm B). Alignment was performed with Tophat_2.0.6. Differential gene expression was analyzed with the Differential Expression analysis for Sequence count data package. Gene fusion was detected with ChimeraScan, TophatFusion and DeFuse tools. Variant calling including variations, insertions and deletions was processed following GATK recommendations for RNAseq datas. Quantitative RT-PCR experiments were done to confirm RNA-seq expression results in patient samples not selected for RNA-seq analysis (validation cohort).
Results: We first analyzed differentially expressed genes (DEGs) between responders and non-responders in pre-treatment or post-treatment samples to select potential predictive markers of response. We identified 51 DEGs before treatment common to anastrozole and fulvestrant. Among these 51 genes, SGK2 was the only gene more intensely expressed in responders than in non-responders. Then we compared DEGs between pre and post-treatment samples for responders or non-reponders for both treatment arms. SGK2 expression remains stable after treatment. Furthermore we identified 7 DEGs specific to responders and 11 DEGs specific to non-responders. Concerning genes fusion detection predicted by at least 2 tools, none was specific to a response type. We noted a higher number of fusions in non-responders samples. Variants detected by RNA-Seq are being confirmed by DNA-Seq using a home-made next-generation sequencing panel including 95 genes frequently mutated in breast cancers (analysis ongoing).
Conclusion:High expression of SGK2, encoding a kinase induced in response to signals that activate PI3kinase, may represent a predictive marker of sensitivity to NET. DEGs associated with NET response or resistance belong to cell cycle, DNA replication and repair, cell death and drug metabolism. Ongoing DNA-seq datas will complete this genomic analysis. This research was conducted with support from AstraZeneca and Institut Curie.
Citation Format: Callens C, Bessoltane N, Ngo C, Chemlali W, Becette V, Bernard V, Delattre O, Lemonnier J, Mouret-Reynier M-A, Andre F, Bieche I, Lerebours F. Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-09.
Collapse
Affiliation(s)
- C Callens
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - N Bessoltane
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - C Ngo
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - W Chemlali
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - V Becette
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - V Bernard
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - O Delattre
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - J Lemonnier
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - M-A Mouret-Reynier
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - F Andre
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - I Bieche
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| | - F Lerebours
- Institut Curie, Paris, France; Unicancer, Paris, France; Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont Ferrand, France
| |
Collapse
|
20
|
Bernard V, Andrašina T, Červinka D, Martiš J, Procházka P, Mornstein V, Válek V. A Thermographic Comparison of Irreversible Electroporation and Radiofrequency Ablation. Ing Rech Biomed 2017. [DOI: 10.1016/j.irbm.2016.11.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
21
|
Delmas O, Garcia P, Bernard V, Fabre M, Vialet R, Boubred F, Fayol L. Devenir à l’âge de 3ans d’une cohorte d’enfants nés à moins de 26 semaines d’aménorrhée. Arch Pediatr 2016; 23:927-34. [DOI: 10.1016/j.arcped.2016.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Revised: 02/25/2016] [Accepted: 06/11/2016] [Indexed: 10/21/2022]
|
22
|
Bordier P, Garrigue S, Bernard V, Haissaguerre M, Douard H, Broustet JP, Clementy J. Flecainide-induced Increase in QRS Duration and Proarrhythmia during Exercise. Clin Drug Investig 2016; 13:326-37. [PMID: 27519494 DOI: 10.2165/00044011-199713060-00005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In patients taking flecainide, exercise-induced arrhythmias are believed to be related to QRS widening at rest and during exercise. Our aim was to determine, retrospectively, predictive factors of flecainide-induced (a) QRS widening at rest and during exercise, and (b) proarrhythmia (PA) during exercise. Flecainide was administered to 119 patients for atrial and/or ventricular arrhythmias who performed a maximal treadmill test. A total of 63 patients had a normal heart (defined by the absence of structural heart disease and an ejection fraction ≥ 55% by echocardiography and/or cardiac catheterisation), 26 had coronaropathy, 18 valvulopathy and 3 had both, and 7 had dilated and 2 hypertrophic cardiomyopathy. The mean dosage of flecainide was 190 or 200 ± 10 mg/day. Previous myocardial infarction (MI) was a predictive variable of flecainide-induced QRS widening at rest (p = 0.04). During exercise, the risk factors of QRS widening were previous MI (p = 0.008), angina without previous MI (p = 0.009), structural heart disease (p = 0.001) and a bundle branch block at rest (p = 0.01). PA on exercise occurred in 7 patients. Structural heart disease (p = 0.04) and an impaired left ventricular ejection fraction (LVEF) [p = 0.02] were predictive variables of PA. All patients with left ventricular dysfunction and PA had a QRS widening with flecainide at rest ≥ 25%. The risk factors of QRS widening at rest and during exercise with flecainide were distinct from those of PA on exercise. In patients with an impaired LVEF, a flecainide-induced QRS widening of 25% at rest was the threshold value beyond which there was a high risk of PA during exercise. This study was retrospective and not a double-blind trial, therefore the results need to be corroborated in a prospectively designed trial.
Collapse
Affiliation(s)
- P Bordier
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| | - S Garrigue
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| | - V Bernard
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| | - M Haissaguerre
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| | - H Douard
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| | - J P Broustet
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| | - J Clementy
- Hôpital Cardiologique du Haut-Leveque, University of Bordeaux II, Pessac, France
| |
Collapse
|
23
|
Poirier N, Pengam S, Dilek N, Claire U, Bernard M, Daguin V, Vanessa G, Gilles B, Bernard V. Control of immune tolerance by the SIRPα-CD47 pathway and myeloid-derived suppressor cells. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61762-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Jauffret C, Coutherut J, Bernard V, Marty N, Briend-Godet V, Scanvion A, Biron C. SP-04 - Vers une amélioration du parcours des usagers entre une pass et un centre de prévention des maladies infectieuses et transmissibles. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30505-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
|
26
|
San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol 2015; 27:635-41. [PMID: 26681674 PMCID: PMC4803451 DOI: 10.1093/annonc/mdv604] [Citation(s) in RCA: 148] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 12/07/2015] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND The ability to perform comprehensive profiling of cancers at high resolution is essential for precision medicine. Liquid biopsies using shed exosomes provide high-quality nucleic acids to obtain molecular characterization, which may be especially useful for visceral cancers that are not amenable to routine biopsies. PATIENTS AND METHODS We isolated shed exosomes in biofluids from three patients with pancreaticobiliary cancers (two pancreatic, one ampullary). We performed comprehensive profiling of exoDNA and exoRNA by whole genome, exome and transcriptome sequencing using the Illumina HiSeq 2500 sequencer. We assessed the feasibility of calling copy number events, detecting mutational signatures and identifying potentially actionable mutations in exoDNA sequencing data, as well as expressed point mutations and gene fusions in exoRNA sequencing data. RESULTS Whole-exome sequencing resulted in 95%-99% of the target regions covered at a mean depth of 133-490×. Genome-wide copy number profiles, and high estimates of tumor fractions (ranging from 56% to 82%), suggest robust representation of the tumor DNA within the shed exosomal compartment. Multiple actionable mutations, including alterations in NOTCH1 and BRCA2, were found in patient exoDNA samples. Further, RNA sequencing of shed exosomes identified the presence of expressed fusion genes, representing an avenue for elucidation of tumor neoantigens. CONCLUSIONS We have demonstrated high-resolution profiling of the genomic and transcriptomic landscapes of visceral cancers. A wide range of cancer-derived biomarkers could be detected within the nucleic acid cargo of shed exosomes, including copy number profiles, point mutations, insertions, deletions, gene fusions and mutational signatures. Liquid biopsies using shed exosomes has the potential to be used as a clinical tool for cancer diagnosis, therapeutic stratification and treatment monitoring, precluding the need for direct tumor sampling.
Collapse
Affiliation(s)
- F A San Lucas
- Department of Translational Molecular Pathology Department of Pathology
| | - K Allenson
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - V Bernard
- Department of Pathology The University of Texas Graduate School of Biomedical Sciences at Houston, Houston
| | | | | | | | - E A Ehli
- Avera Institute for Human Genetics, Sioux Falls
| | - G E Davies
- Avera Institute for Human Genetics, Sioux Falls
| | | | - D Li
- Department of Gastrointestinal (GI) Medical Oncology
| | - R Wolff
- Department of Gastrointestinal (GI) Medical Oncology
| | - M Katz
- Department of Gastrointestinal (GI) Medical Oncology
| | | | - I Wistuba
- Department of Translational Molecular Pathology
| | - A Maitra
- Department of Translational Molecular Pathology Department of Pathology Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, USA
| | | |
Collapse
|
27
|
Knief J, Gebauer N, Bernard V, Schemme J, Reddemann K, Gebauer J, Rades D, Brabant G, Lehnert H, Feller AC, Thorns C. Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large b-cell lymphomas of the thyroid – A study of 21 cases. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Gebauer N, Schmidt-Werthern C, Bernard V, Schemme J, Feller AC, Keck T, Begum N, Rades D, Lehnert H, Brabant G, Thorns C. Genomic landscape of pancreatic neuroendocrine tumors. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Bernard V, Bouvattier C, Christin-Maitre S. [Therapeutic issues concerning male fertility]. Ann Endocrinol (Paris) 2015; 75 Suppl 1:S13-20. [PMID: 25617918 DOI: 10.1016/s0003-4266(14)70023-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Men reproductive health has long been ignored although it is responsible for 50% of couple's infertility. However, in recent years, the understanding of endocrine physiology underlying testis development and spermatogenesis has enabled the development of new therapeutic strategies. Some concern the management of male infertility. Others are dealing with finding an effective male contraceptive. In this review, we first present the management of infertility, in patients with congenital hypogonadotropic hypogonadism. We then describe the major improvements for Klinefelter patient's infertility. Finally, we review the different hormonal and non-hormonal methods for male contraception, currently in development. Efficacy and safety of the some non-hormonal methods remain to be demonstrated so far in humans.
Collapse
Affiliation(s)
- V Bernard
- Unité INSERM 693, 63 rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France.
| | - C Bouvattier
- Service d'endocrinologie et diabétologie pédiatrique, CHU de Bicêtre, Le Kremlin-Bicêtre, France
| | - S Christin-Maitre
- Service d'endocrinologie et maladies de la reproduction, Hôpital Saint-Antoine, Paris, France
| |
Collapse
|
30
|
Pierga J, Decraene C, Bernard V, Kamal M, Blin A, Rio Frio T, Servant N, Bidard F, Paoletti X, Stern M, Lebofsky R, Le Tourneau C. De Novo Mutation Detection from Ctdna Correlates with Variants Detected on Metastasis of Patients with Any Kind of Refractory Cancer from the Shiva Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014; 111:17-24. [PMID: 24762958 PMCID: PMC4090722 DOI: 10.1038/bjc.2014.211] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 03/24/2014] [Accepted: 03/27/2014] [Indexed: 12/24/2022] Open
Abstract
Background: The SHIVA trial is a multicentric randomised proof-of-concept phase II trial comparing molecularly targeted therapy based on tumour molecular profiling vs conventional therapy in patients with any type of refractory cancer. Results of the feasibility study on the first 100 enrolled patients are presented. Methods: Adult patients with any type of metastatic cancer who failed standard therapy were eligible for the study. The molecular profile was performed on a mandatory biopsy, and included mutations and gene copy number alteration analyses using high-throughput technologies, as well as the determination of oestrogen, progesterone, and androgen receptors by immunohistochemistry (IHC). Results: Biopsy was safely performed in 95 of the first 100 included patients. Median time between the biopsy and the therapeutic decision taken during a weekly molecular biology board was 26 days. Mutations, gene copy number alterations, and IHC analyses were successful in 63 (66%), 65 (68%), and 87 (92%) patients, respectively. A druggable molecular abnormality was present in 38 patients (40%). Conclusions: The establishment of a comprehensive tumour molecular profile was safe, feasible, and compatible with clinical practice in refractory cancer patients.
Collapse
Affiliation(s)
- C Le Tourneau
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France [3] Institut Curie, Saint-Cloud, France
| | - X Paoletti
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | - N Servant
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | | | | | | | | | - J Romejon
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | | | - P Huppe
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | - F Mulot
- Institut Curie, Paris, France
| | | | - J Wong
- Institut Curie, Paris, France
| | | | | | - C Reyes
- Institut Curie, Paris, France
| | - E Henry
- Institut Curie, Paris, France
| | - Q Leroy
- Institut Curie, Paris, France
| | - P Gestraud
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | - P La Rosa
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | - E Mitry
- Institut Curie, Saint-Cloud, France
| | - O Trédan
- Centre Léon Bérard, Lyon, France
| | - J-P Delord
- Institut Claudius Régaud, Toulouse, France
| | - M Campone
- Centre René Gauducheau, Nantes, France
| | | | - N Isambert
- Centre Georges-François Leclerc, Dijon, France
| | | | - M Kamal
- Institut Curie, Paris, France
| |
Collapse
|
32
|
Weynand B, Borbath I, Bernard V, Sempoux C, Gigot JF, Hubert C, Lannoy V, Deprez PH, Jouret-Mourin A. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. Cytopathology 2013; 25:389-95. [PMID: 24750272 DOI: 10.1111/cyt.12111] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/25/2013] [Indexed: 12/30/2022]
Abstract
OBJECTIVES Assessment of proliferation by the Ki-67 labelling index (Ki67-LI) is an important parameter of pancreatic neuroendocrine tumour (pNET) prognosis on resection specimens. Ki67-LI values for grading are not fully established on endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). The aim of the study was to determine the accuracy of Ki67-LI on EUS-FNA to predict a final grade of pNET and to analyse the relationship between cytological grading and progression-free survival (PFS). METHODS Between 1996 and 2010, 46 pNETs (33 were resected) from 45 patients were diagnosed by EUS-FNA. Ki67-LI was evaluated on cytological and histological material for each tumour and classified according to the 2010 WHO grading system. RESULTS A very good inter-observer agreement for Ki67-LI on EUS-FNA and surgical specimens, respectively, were obtained. Discrepancies were observed between histology and cytology, especially in grade 2 (G2) tumours, where cytology underestimated grading owing to tumour heterogeneity. Still, EUS-FNA was able to distinguish a poor prognostic group, as the actuarial PFS of cytological (c) G3 tumours was 10 ± 4 months versus 29 ± 7 and 68 ± 10 for cG2 and cG1 tumours, respectively (P < 0.0001). CONCLUSION This study attests the reproducibility of Ki67-LI of pNETs whether counted on cytology or histology with a very good inter-observer correlation. Determination of Ki67-LI on EUS-FNA of pNETs should be included systematically in their prognostic work-up.
Collapse
Affiliation(s)
- B Weynand
- Department of Pathology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bernard V, Staffa E, Mornstein V, Bourek A. Infrared camera assessment of skin surface temperature – Effect of emissivity. Phys Med 2013; 29:583-91. [DOI: 10.1016/j.ejmp.2012.09.003] [Citation(s) in RCA: 103] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2012] [Revised: 09/25/2012] [Accepted: 09/28/2012] [Indexed: 11/16/2022] Open
|
34
|
Zühlke C, Bernard V, Stricker S, Kreuz F, Gillessen-Kaesbach G. Mutationen im Senataxin-Gen: Ursache für Ataxie, amyotrophe Lateralsklerose oder Tremor. Akt Neurol 2009. [DOI: 10.1055/s-0029-1223410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Bernard V, Aguilera D, Alves P, Aslangul E, Le Jeunne C, Perrot S. Dermatomyosite induite par l’infliximab au cours d’une maladie de Still de l’adulte. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Benchimol D, Mazanof M, Dubroca B, Benchimol H, Bernard V, Couffinhal T, Dartigues JF, Roudaut R, Pillois X, Bonnet J. Detection of coronary stenoses by stress echocardiography using a previously implanted pacemaker for ventricular pacing: preliminary report of a new method. Clin Cardiol 2009; 23:842-8. [PMID: 11097132 PMCID: PMC6655253 DOI: 10.1002/clc.4960231111] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND The number of patients with pacemakers has been increasing and a large number of them will present with chest pain or symptoms suggesting angina pectoris. Myocardial ischemia and presence of coronary artery disease are difficult to detect and assess by noninvasive methods in patients with a pacemaker; the electrocardiogram (ECG) at rest and during exercise is usually very difficult to analyze in terms of ischemia or even presence of an acute myocardial infarction. HYPOTHESIS To detect significant coronary stenosis in patients with previously implanted pacemakers, we tested a new stress echocardiography method using incremental ventricular pacing by already implanted pacemakers. METHODS We studied prospectively 25 consecutive patients who underwent stress echocardiography with increasing ventricular pacing up to either 85% of the age-predicted maximal heart rate or chest pain. Positive tests were defined by new hypokinesia or worsening of a preexisting alteration in wall motion in at least two adjacent territories. All patients underwent coronary angiograms to define the presence and severity of coronary stenoses. RESULTS Among the 25 tests, 11 (44%) were stopped for chest pain. 1 (4%) for moderate discomfort, 1 (4%) for a drop in blood pressure, and the target pacing rate was achieved in the tests of the remaining 12 patients (48%). There were no complications. Thirteen patients had significant stenoses. In 10 cases, stress echocardiography was a true positive test with respect to coronary angiography. There were 11 true negative, 1 false positive, and 3 false negative tests. The sensitivity was 77%, specificity was 90%, the positive predictive value was 91%, and the negative predictive value 79%. The accuracy was 84%. CONCLUSIONS This new stress echocardiography method appears feasible, easy, safe, and effective for detection of significant coronary stenoses in patients with pacemakers.
Collapse
Affiliation(s)
- D Benchimol
- Service de Cardiologie et Maladies Vasculaires, Hôpital Cardiologique, Pessac, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Bernard V, Stricker S, Kreuz F, Minnerop M, Gillessen-Kaesbach G, Zühlke C. Ataxia with oculomotor apraxia type 2: novel mutations in six patients with juvenile age of onset and elevated serum alpha-fetoprotein. Neuropediatrics 2008; 39:347-50. [PMID: 19569000 DOI: 10.1055/s-0029-1214424] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Ataxia with oculomotor apraxia type 2 (AOA2), a neurodegenerative disorder with juvenile to adolescent onset is caused by mutations within the SENATAXIN gene ( SETX). We performed molecular analyses in six patients showing clinically an AOA2 phenotype and moderate to significant elevated serum alpha-fetoprotein levels. Sequencing the 24 coding exons and flanking intronic sequences revealed 11 novel DNA variations, including seven unknown missense mutations, a dinucleotide deletion, a four-nucleotide deletion affecting the 5' splice site of exon 22 and two sequence variations, which are considered to be polymorphisms. By molecular testing the clinical diagnosis has been confirmed in all patients.
Collapse
Affiliation(s)
- V Bernard
- Institut für Humangenetik, Universität zu Lübeck, Lübeck, Germany.
| | | | | | | | | | | |
Collapse
|
38
|
Weigang E, Luehr M, von Samson P, Hartert M, Goebel H, Wetzig M, Bernard V, Siegenthaler MP, Beyersdorf F. Development of a Special Balloon Occlusion Device to Prevent Adverse Events in High-Risk Patients during Open Aortic Surgery. Eur Surg Res 2008; 37:204-9. [PMID: 16260869 DOI: 10.1159/000087864] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2005] [Accepted: 07/08/2005] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To prevent clamp injury that may occur during aortic surgery, we aimed to develop a special balloon occlusion (BO) device to lower the thromboembolic risk in patients with severe atherosclerosis during aortic aneurysm repair. METHODS The study comprised two test phases: a laboratory-testing series focussing on flexible artificial aortas, and an experimental series conducted on 10 pigs. RESULTS The device proved to be effective during the laboratory tests and the experiments on pigs. No complications such as intraoperative balloon rupture, dislocation, or occlusion leaks occurred. No damage to the aortic vessels was observed in further histological examinations. CONCLUSIONS This BO device has the potential to become an alternative to cross-clamping for vascular surgeons in patients with severely atherosclerotic vessels.
Collapse
Affiliation(s)
- E Weigang
- Department of Cardiovascular Surgery, University Hospital Freiburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hellenbroich Y, Bernard V, Zühlke C. Spinocerebellar ataxia type 4 and 16q22.1-linked Japanese ataxia are not allelic. J Neurol 2008; 255:612-3. [DOI: 10.1007/s00415-008-0771-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 09/13/2007] [Accepted: 10/09/2007] [Indexed: 12/30/2022]
|
40
|
Bernard V, Skorpíková J, Mornstein V. The combined effect of ultrasound exposure and cisplatin on human ovarian carcinoma cells A2780. Folia Biol (Praha) 2008; 54:97-101. [PMID: 18647549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
This article deals with an in vitro study of the effect of cisplatin and low intensity ultrasound exposure on the viability of human ovarial carcinoma cells A2780. The effect on the viability of 103 cell experimental group samples under the influence of separate and combined cisplatin and ultrasound far field exposure was studied. Viable cells in individual experimental groups were followed at time intervals of 0, 24, 48 and 72 hours following treatment. Another objective of the study was to investigate the effect of the experimental protocol on the combined effect of cisplatin and ultrasound exposure. The effect of the concurrent application of cisplatin and ultrasound exposure was compared with that in which cisplatin was added to the cell suspension after ultrasound exposure. The results of this work confirmed the cytotoxicity of cisplatin and possible stimulation of cancer cells by low intensity ultrasound. However, it was found that ultrasound exposure enhances the action of cisplatin on the viability of A2780 cells and that the effect is dependent on the experimental protocol. In this case the concurrent application of cisplatin and ultrasound was found to be more effective (P < 0.05).
Collapse
Affiliation(s)
- V Bernard
- Department of Biophysics, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | | | | |
Collapse
|
41
|
Blois-Heulin C, Bernard V, Bec P. Postural effect on manual laterality in different tasks in captive grey-cheeked mangabey (Lophocebus albigena). ACTA ACUST UNITED AC 2007; 121:205-13. [PMID: 17516799 DOI: 10.1037/0735-7036.121.2.205] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The authors examined the effects of task complexity and posture on laterality and compared lateralization during different tasks in 9 captive grey-cheeked mangabeys (Lophocebus albigena) during spontaneous food processing and 3 experimental tasks. Comparisons with data of red-capped mangabeys (Cercocebus torquatus torquatus; semiterrestrial species) were used. Less than half the monkeys were lateralized for simple everyday activities, but 6 were lateralized for complex daily activities. Moreover, all the monkeys were lateralized when performing experimental tasks. Laterality at the group level was found for the bipedal task: Mangabeys were right-handed. Complexity of tasks increases laterality at the individual level. Significant differences between the 2 species of mangabeys were found, allowing us to confirm that postural constraints are a major factor in the emergence of group handedness.
Collapse
Affiliation(s)
- C Blois-Heulin
- Station biologique, University of Rennes, Centre National de la Recherche Scientifique, Paimpoint, France.
| | | | | |
Collapse
|
42
|
Abstract
Autosomal recessive cerebellar ataxias are a phenotypically and genetically heterogeneous group of diseases. Major forms can be distinguished on the basis of clinical signs, age of onset, biochemical parameters or genotypes. To develop rational diagnostic strategies, phenotypic information, e.g., age of onset combined with population-specific disease frequencies could be highly favourable. We tested this hypothesis for single candidate loci and mutations in North European ataxia patients with juvenile and early adult onset. While we could prove that Friedreich ataxia (FRDA) is frequent in Germany, only few patients with ataxia-oculomotor apraxia type 1 (AOA1) and type 2 (AOA2) were diagnosed. The frequency of the mitochondrial recessive ataxia syndrome (MIRAS) and the infantile onset spinocerebellar ataxia (IOSCA) in this population remains unknown since no case with the common mutation of the corresponding gene was detected.
Collapse
Affiliation(s)
- C Zühlke
- Institut für Humangenetik, Universität zu Lübeck, Lübeck, Germany.
| | | | | |
Collapse
|
43
|
Le Moine C, Bernard V, Bloch B. Quantitative in situ hybridization using radioactive probes in the study of gene expression in heterocellular systems. Methods Mol Biol 2003; 33:301-11. [PMID: 7894584 DOI: 10.1385/0-89603-280-9:301] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- C Le Moine
- URA CNRS Laboratoire d'Histologie-Embryologie, Université de Bordeaux II, France
| | | | | |
Collapse
|
44
|
Guis S, Bendahan D, Kozak-Ribbens G, Figarella-Branger D, Mattei JP, Pellissier JF, Treffouret S, Bernard V, Lando A, Cozzone PJ. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49:237-8. [PMID: 12687516 DOI: 10.1002/art.11013] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S Guis
- Centre de Résonance Magnétique Biologique et Médicale, Faculté de Médicine, Marseille, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, Gasnier B, Giros B, El Mestikawy S. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. J Neurosci 2001; 21:RC181. [PMID: 11698619 PMCID: PMC6762292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
Before their exocytotic release during stimulation of nerve terminals, nonpeptide neurotransmitters are loaded into synaptic vesicles by specific transporters. Recently, a protein initially identified as brain-specific Na(+)-dependent inorganic phosphate transporter I (BNPI) has been shown to represent a vesicular glutamate transporter (VGLUT1). In this study, we investigated whether a highly homologous "differentiation-associated Na(+)-dependent inorganic phosphate transporter" (DNPI) is involved in glutamatergic transmission. Vesicles isolated from BON cells expressing recombinant DNPI accumulated l-glutamate with bioenergetical and pharmacological characteristics identical to those displayed by VGLUT1 and by brain synaptic vesicles. Moreover, DNPI localized to synaptic vesicles, at synapses exhibiting classical excitatory features. DNPI thus represents a novel vesicular glutamate transporter (VGLUT2). The distributions of each VGLUT transcript in brain were highly complementary, with only a partial regional and cellular overlap. At the protein level, we could only detect either VGLUT1- or VGLUT2-expressing presynaptic boutons. The existence of two VGLUTs thus defines distinct subsets of glutamatergic neurons.
Collapse
Affiliation(s)
- E Herzog
- Institut National de la Santé et de la Recherche Médicale U513, Faculté de Médecine, 94010 Créteil Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Increasing use of herbaceous legumes such as mucuna ( Mucuna pruriens var. utilis [Wright] Bruck) and lablab ( Lablab purpureus [L.] Sweet) in the derived savannas of West Africa can be attributed to their potential to fix atmospheric nitrogen (N2). The effects of management practices on N2 fixation in mucuna and lablab were examined using 15N isotope dilution technique. Dry matter yield of both legumes at 12 weeks was two to five times more in in situ mulch (IM) than live mulch (LM) systems. Land Equivalent Ratios, however, showed 8 to 30% more efficient utilization of resources required for biomass production under LM than IM systems. Live mulching reduced nodule numbers in the legumes by one third compared to values in the IM systems. Similarly, nodule mass was reduced by 34 to 58% under LM compared to the IM systems. The proportion of fixed N2 in the legumes was 18% higher in LM than IM systems. Except for inoculated mucuna, the amounts of N fixed by both legumes were greater in IM than LM systems. Rhizobia inoculation of the legumes did not significantly increase N2 fixation compared to uninoculated plots. Application of N fertilizer reduced N2 fixed in the legumes by 36 to 51% compared to inoculated or uninoculated systems. The implications of cover cropping, N fertilization, and rhizobia inoculation on N contributions of legumes into tropical low-input systems were discussed.
Collapse
Affiliation(s)
- B Ibewiro
- Laboratory of Soil Fertility and Soil Biology, Katholieke Universiteit Leuven, Heverlee, Belgium.
| | | | | | | | | |
Collapse
|
47
|
Laffon E, Laurent F, Bernard V, De Boucaud L, Ducassou D, Marthan R. Noninvasive assessment of pulmonary arterial hypertension by MR phase-mapping method. J Appl Physiol (1985) 2001; 90:2197-202. [PMID: 11356783 DOI: 10.1152/jappl.2001.90.6.2197] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We describe a magnetic resonance (MR) imaging method that emphasizes pressure wave velocity to noninvasively assess pulmonary arterial hypertension. Both the blood flow and the corresponding vessel cross-sectional area (CSA) were measured by MR phase mapping in the main pulmonary artery (MPA) in 15 patients. MPA pressures were also measured, in the same patients, by right-side heart catheterization. Two significant relationships were established: 1) between the pressure wave velocity in the MPA and the mean pressure in the MPA (Ppa) writing pressure wave velocity = 9.25 Ppa − 202.51 ( r = 0.82) and 2) between the ratio of pressure wave velocity to the systolic blood velocity peak in the MPA (R) and the mean pressure in the MPA writing R = 0.68 Ppa − 4.33 ( r = 0.89). Using these relationships, we estimated two pressure values to frame the actual Ppa value in each patient from the present series with a reasonable reliability percentage (87%).
Collapse
Affiliation(s)
- E Laffon
- Service de Médecine Nucléaire, Hôpital du Haut-Lévêque, 33604 Pessac, France.
| | | | | | | | | | | |
Collapse
|
48
|
Csaba Z, Bernard V, Helboe L, Bluet-Pajot MT, Bloch B, Epelbaum J, Dournaud P. In vivo internalization of the somatostatin sst2A receptor in rat brain: evidence for translocation of cell-surface receptors into the endosomal recycling pathway. Mol Cell Neurosci 2001; 17:646-61. [PMID: 11312601 DOI: 10.1006/mcne.2000.0958] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
To determine whether cellular compartmentalization of somatostatin receptors can be regulated in vivo, we examined the immunocytochemical distribution of the sst2A receptor (sst2AR) after stereotaxical injections of somatostatin analogs into the rat parietal cortex. Whereas CH-275, a sst1R agonist, failed to induce changes in the diffuse sst2AR immunostaining pattern characteristic of control animals, somatodendritic profiles displaying intracytoplasmic immunoreactive granules became apparent short-term after injection of either somatostatin or the sst2R agonist octreotide. Confocal microscopy revealed that 90% of sst2AR-immunoreactive endosome-like organelles displayed transferrin receptor immunoreactivity. At the electron microscopic level, the percentage of sst2AR immunoparticles dramatically decreased at the plasmalemma of perikarya and dendrites after octreotide injection. Conversely, it significantly increased in endosomes-like organelles. These results demonstrate that sst2ARs undergo, in vivo, rapid and massive internalization into the endocytic recycling compartment in response to acute agonist stimulation and provide important clues toward elucidating somatostatin receptor signaling in the mammalian brain.
Collapse
Affiliation(s)
- Z Csaba
- INSERM U549, IFR Broca-Sainte Anne, Centre Paul Broca, Paris, 75014, France
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
Glutamatergic neurotransmission in the substantia nigra pars compacta and pars reticulata is mediated through N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxaline propionic acid/kainate (AMPA) type receptors as well as other glutamate receptors and is critical for basal ganglia functioning. A major glutamatergic input to the substantia nigra originates in the subthalamic nucleus, and the long-lasting stimulation of the dopaminergic cells of the substantia nigra pars compacta by the subthalamic neurons has been implicated in the pathophysiology of Parkinson's disease. The objectives of the present study were to determine the subcellular and subsynaptic localization of subunits of the N-methyl-D-aspartate and AMPA receptors in the substantia nigra, and also to determine whether co-localization of N-methyl-D-aspartate and AMPA receptor subunits occur at individual synapses. To achieve this, pre-embedding and post-embedding immunocytochemistry was applied to sections of substantia nigra using antibodies that recognize the NR1 and NR2A/B subunits of the N-methyl-D-aspartate receptor, and GluR2/3 subunits of the AMPA receptor. In both regions of the substantia nigra, immunolabelling for each of the subunits was observed in numerous perikarya and proximal dendrites. At the subcellular level, silver-intensified immunogold particles localizing N-methyl-D-aspartate and AMPA receptor subunits were most commonly present within dendrites where they were associated with a variety of intracellular organelles and with the internal surface of the plasma membrane. Post-embedding immunogold labelling revealed immunoparticles labelling for NR1, NR2A/B and GluR2/3 to be enriched at asymmetric synaptic specializations, although a large proportion of asymmetric synapses were immunonegative. Double immunolabelling revealed, in addition to single-labelled synapses, the co-localization of subunits of the N-methyl-D-aspartate receptor and subunits of the AMPA receptor at individual asymmetric synapses. Similarly, double immunolabelling also revealed the co-localization of the NRl and NR2A/B subunits of the N-methyl-D-aspartate receptor at individual asymmetric synapses. Labelling for NR1 and GluR2/3 was, on average, relatively evenly distributed across the width of the synapse with a gradual reduction towards the periphery when analysed in single sections. In summary, the present results demonstrate that AMPA and N-methyl-D-aspartate receptors are selectively localized at a subpopulation of asymmetric synapses in the substantia nigra pars compacta and reticulata and that the two receptor types, at least partially co-localize at individual synapses. It is concluded that glutamatergic transmission in the substantia nigra pars compacta and pars reticulata occurs primarily at asymmetric synapses and, at least in part, is mediated by both N-methyl-D-aspartate and AMPA receptors.
Collapse
Affiliation(s)
- B T Chatha
- MRC Anatomical Neuropharmacology Unit, Department of Pharmacology, Mansfield Road, OX1 3TH, Oxford, UK
| | | | | | | |
Collapse
|
50
|
Laffon E, Bernard V, Montaudon M, Marthan R, Barat JL, Laurent F. Tuning of pulmonary arterial circulation evidenced by MR phase mapping in healthy volunteers. J Appl Physiol (1985) 2001; 90:469-74. [PMID: 11160044 DOI: 10.1152/jappl.2001.90.2.469] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Magnetic resonance (MR) phase mapping was used to noninvasively assess both blood flow and cross-sectional area (CSA) in the main pulmonary artery (MPA) of 12 healthy volunteers. Flow and CSA patterns exhibited two positive peaks: high systolic and small diastolic. This finding can be explained using a simple "distributed" theoretical model that takes into account the role of a reflected pressure wave from pulmonary vascular impedance in generating a diastolic flow. The mean reflection coefficient of pressure wave, MPA input impedance, and pulmonary vascular impedance were assessed. We verified, in this series, that pressure wave velocity appears to be age-dependent. MR phase mapping has been used to observe the tuning (resonance) of the right cardiovascular system at rest under physiological conditions. MR phase mapping could be used to assess pathological modifications of the tuning that occurs in cases of pulmonary arterial hypertension.
Collapse
Affiliation(s)
- E Laffon
- Service de Médecine Nucléaire, Hôpital du Haut-Lévêque, 33604 Pessac, France.
| | | | | | | | | | | |
Collapse
|